Congenital myopathy has recently been associated with biallelic pathogenic variants in the *SCN4A* gene that encodes the voltage-dependent sodium channel Na~V~1.4.^[@R1],[@R2]^ In 13 previously reported cases,^[@R1],[@R2]^ 7 died *in utero* or shortly after birth. The 6 survivors showed features consistent with "classical" congenital myopathy. Here, we report 2 new familial cases with variable phenotype.

Written informed consent was obtained from both patients. Permission for the study was granted by the Danish Data Protection Agency.

The index patient, an 18-year-old woman, born as the second of 2 children to consanguineous parents, reported weakness and dyspnea from early childhood. Pregnancy and birth were normal, but postpartum, she had dysphagia and was tube fed. Early motor milestones were delayed, with independent ambulation achieved at age 2.25 years and inability to lift her head from a supine position until age 3 years. She experienced improvement in her condition throughout childhood, but still had reduced walking distance (2.5 km), difficulty lifting heavy objects, and experienced patella luxations.

On examination, the patient is 150 cm tall and has a dolichocephalic head shape and elbow hypermobility ([figure 1A](#F1){ref-type="fig"}). Strength testing showed diffuse muscle force reduction at Medical Research Council (MRC) grade 4, with no distal/proximal gradient, and axial weakness. Spirometry showed normal forced vital capacity (FVC) (88%) and forced expiratory volume (FEV1) (96%).

![Clinical features in sisters with SCN4A congenital myopathy\
Featuring the dococephalic head form in the index patient (left image) and hypermobility of the elbows in both sisters (middle and right image) (A). T1-weighted muscle MRI images of the index patient show severe fatty infiltration and atrophy of gluteus medius (arrows, left image) and adductor magnus and, to a lesser degree, the hamstrings bilaterally (right image) (B).](NG2018008714FF1){#F1}

Creatine kinase (CK) levels and neurophysiologic findings were normal. Replacement of muscle by fat on MRI was pronounced in gluteus maximus and hamstring muscles ([figure 1B](#F1){ref-type="fig"}). Muscle biopsy, at age 4 years, displayed myopathic features with varying fiber size, increased number of internalized nuclei, atrophic fibers, and endomysial fibrosis and fat infiltration.

Next-generation sequencing revealed homozygosity for a previously described missense variant in *SCN4A* (NM_000334.4: c.3425G\>A(p.Arg.1142Gln)),^[@R2]^ confirmed through Sanger sequencing, and was deemed to be pathogenic by 6 prediction tools. Parents were heterozygous for the variant.

The 22-year-old sister of the index patient was also homozygous for Arg1142Gln. She had milder muscular complaints than her sister, which included difficulties lifting her head when lying down, exertional shortness of breath, and poor cycling capacity since childhood. She had elbow joint hypermobility like her sister. Her motor milestones were normal. Strength testing showed reduced neck flexion (MRC 4+), shoulder abduction (MRC4+), and hip flexion (MRC 4+). CK, lung function tests, and MRI of thigh muscles were normal.

Functional assessment of the Arg1142Gln (R1142Q) variant in human embryonic kidney 293 (HEK293) cells revealed partial loss-of-function effects ([figure 2](#F2){ref-type="fig"}), as previously reported in *SCN4A*-related congenital myopathy.^[@R1],[@R2]^ Na~V~1.4 R1142Q peak current density was significantly lower than wild type (WT) (WT: 106.4 ± 12.4 pA/pF, R1142Q: −39.0 ± 6.4 pA/pF at 5 mV, [figure 2, A and B](#F2){ref-type="fig"}), and the voltage dependence of channel activation was significantly changed ([figure 2, C and D](#F2){ref-type="fig"}).

![The mutation R1142Q causes loss-of-function of Na~V~1.4 current\
(A) Representative current traces for Na~V~1.4 WT and R1142Q recorded from transiently transfected HEK293 cells. (B) I/V relationship for the peak current density for Na~V~1.4 WT (n = 9) and R1142Q (n = 8). Voltage protocol shown as inset. (C) Steady-state inactivation and activation curves for Na~V~1.4 WT (black) and R1142Q (gray). Voltage protocol shown as inset. (D) Comparison of activation V~50~ values between Na~V~1.4 WT (black) and R1142Q (gray). \**p* \< 0.05; \*\**p* \< 0.006; \*\*\*\**p* \< 0.0001.](NG2018008714FF2){#F2}

Variants in *SCN4A* were originally linked to congenital myasthenia,^[@R3],[@R4]^ but recently, also to severe fetal hypokinesia and early lethality^[@R1]^ and to sudden infant death syndrome.^[@R5]^ A strikingly milder phenotype of "classical" congenital myopathy has been described in 6 patients with *SCN4A* variants in a recessive pattern, only 3 of whom were adults (aged 18--35 years old).^[@R1],[@R2]^ Our 18-year-old index patient exhibited a phenotype similar to that previously reported,^[@R1]^ while her 20-year-old sister was only marginally affected. Our index patient\'s characteristic muscle MRI findings were similar to 4 other patients with *SCN4A* mutations, including 2 brothers, compound heterozygous for c.3425G\>A(p.Arg1142Gln) and another missense variant c.1123T\>C (p.Cys375Arg).^[@R1],[@R2]^ The brothers, unlike our patients, had elongated faces, ptosis, facial weakness, scoliosis, and elevated CK.^[@R2]^ We speculate whether homozygosity for the p.Arg1142Gln variant conferred the milder phenotype observed in our patients. The present report expands our knowledge regarding *SCN4A*-related congenital myopathy in adulthood and underscores that the phenotype of this disorder may vary considerably, even within members of the same family, as in other recessive channelopathies affecting muscles.^[@R6]^
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